SeaGen FDA Deadline Set for Aug. 30

Xconomy Seattle — 

Seattle Genetics (NASDAQ: SGEN) said today that the FDA has agreed to provide a faster-than-usual six-month review of its application to start selling brentuximab vedotin (SGN-35) for the treatment of patients with Hodgkin’s disease and anaplastic large cell lymphoma. The agency now has until August 30 to decide whether the drug is ready for sale in the U.S. The FDA usually takes 10 months to review new drug applications, but it sometimes speeds up the process for potentially groundbreaking or lifesaving new therapies.